Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Silvia La Monica's publication output changed over time?
ScholarIQpublication output · 2002–2023
Output grew0% over the shown period — from 1 works in 2002 to 1 in 2023.
1
1
1
1
2
1
2
1
1
200220052009201220172018201920222023
What are the most-cited papers on Silvia La Monica?
ScholarIQmost cited works
Human myeloma cells stimulate the receptor activator of nuclear factor-κB ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease
Nicola Giuliani, Simona Colla, Roberto Sala, Matteo Moroni, Mirca Lazzaretti, Silvia La Monica, Sabrina Bonomini, Magda Hojden, Gabriella Sammarelli, Sophie Barillé‐Nion, Régis Bataille, Vittorio Rizzoli
Blood. 2002266 CitationsOPEN ACCESS
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells
Daniele Cretella, Andrea Ravelli, Claudia Fumarola, Silvia La Monica, Graziana Digiacomo, Andrea Cavazzoni, Roberta Alfieri, Alessandra Biondi, Daniele Generali, Mara Bonelli, Pier Giorgio Petronini
Journal of Experimental & Clinical Cancer Research. 2018106 CitationsOPEN ACCESS
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells
Mara Bonelli, Graziana Digiacomo, Claudia Fumarola, Roberta Alfieri, Federico Quaini, Angela Falco, Denise Madeddu, Silvia La Monica, Daniele Cretella, Andrea Ravelli, Paola Ulivi, Michela Tebaldi, Daniele Calistri, Angelo Delmonte, Luca Ampollini, Paolo Carbognani, Marcello Tiseo, Andrea Cavazzoni, Pier Giorgio Petronini
S20008548. 2017105 CitationsOPEN ACCESS
Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation
Mara Bonelli, Silvia La Monica, Claudia Fumarola, Roberta Alfieri
Biochemical Pharmacology. 201998 Citations
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
Silvia La Monica, Daniele Cretella, Mara Bonelli, Claudia Fumarola, Andrea Cavazzoni, Graziana Digiacomo, Lisa Flammini, Elisabetta Barocelli, Roberta Minari, Nadia Naldi, Pier Giorgio Petronini, Marcello Tiseo, Roberta Alfieri
Journal of Experimental & Clinical Cancer Research. 201789 CitationsOPEN ACCESS
Related on ScholarIQ
University of Parma
Institution
Human myeloma cells stimulate the receptor activator of nuclear factor-κB ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease
Paper
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells
Paper
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells
Paper
Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation
Paper
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
Paper